Deutsche medizinische Wochenschrift (1946) · 2014
[Symptomatic therapy of SIADH in small cell lung cancer by tolvaptan].
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schnaiter A, Hiddemann W
Аннотация
HISTORY AND CLINICAL FINDINGS: A 69-year-old woman with small cell lung cancer presented in the emergency ward because of severe back pain. She had received tolvaptan treatment in hospital for paraneoplastic SIADH but had discontinued the drug after discharge from hospital 3 days ago. Restriction of fluid intake was not tolerated.
INVESTIGATIONS: Consistent with SIADH, there were profound hyponatraemia, elevated urine osmolality and urine sodium.
TREATMENT AND COURSE: After a generalized seizure triggered by hyponatraemia, tolvaptan was reintroduced in addition to radiochemotherapy. Serum sodium concentration increased and finally returned to normal.
CONCLUSION: If restriction of fluid intake is not tolerated by the patients the vasopressin antagonist tolvaptan provides an alternative symptomatic treatment of paraneoplastic SIADH.
INVESTIGATIONS: Consistent with SIADH, there were profound hyponatraemia, elevated urine osmolality and urine sodium.
TREATMENT AND COURSE: After a generalized seizure triggered by hyponatraemia, tolvaptan was reintroduced in addition to radiochemotherapy. Serum sodium concentration increased and finally returned to normal.
CONCLUSION: If restriction of fluid intake is not tolerated by the patients the vasopressin antagonist tolvaptan provides an alternative symptomatic treatment of paraneoplastic SIADH.